Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

ded September 30, 2009, loss from continuing operations before income taxes was $4.9 million compared to a loss from continuing operations before income taxes of $7.4 million for the nine months ended September 30, 2008.

Clarient's net loss for the third quarter 2009 was $3.2 million, or ($0.04) per share applicable to common stockholders. In the third quarter of 2008, the Company reported a net loss of $2.2 million, or ($0.03) per share applicable to common stockholders.

For the nine months ended September 30, 2009 and 2008, the net loss was $3.4 million and $7.4 million, respectively. Net loss per share applicable to common stockholders for the nine months ended September 30, 2009 and 2008 was ($0.10) and ($0.10), respectively.

Adjusted EBITDA (defined below) for the 2009 third quarter was a negative $1.6 million, compared to adjusted EBITDA of $1.4 million in the third quarter of 2008. For the 2009 nine-month period, adjusted EBITDA was $3.1 million, compared to adjusted EBITDA of $2.6 million in the prior year period, an increase of 19 percent.

Operating expenses were $14.7 million for the third quarter of 2009, compared to $10.2 million in the same quarter of 2008. For the first nine months of 2009, operating expenses totaled $40.5 million, compared to $29.0 million in the year-earlier period. The increase in operating expenses in the third quarter of 2009 versus the comparable period in 2008 was largely related to additional sales and marketing personnel costs and investment in our information technology infrastructure.

At September 30, 2009, Clarient's cash and cash equivalents totaled $8.1 million compared with $1.8 million at December 31, 2008.

Ray Land, Senior Vice President and Chief Financial Officer, said, "In the long term we will greatly benefit from the changes we made this quarter. The new information will allow us to better estimate our expected reimbursement rates, give us
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... Wednesday of last week RENU 28, the world's first and ... for purchase in Australia and New Zealand, and the response ... is, if you think about the definition of aging, it's ... within your body. If you think about the definition of ... What RENU 28 does is it works with these tiny ...
(Date:8/20/2014)... Neurotrope, Inc. (OTCQB: NTRP) today announced ... provide an update on Company activities. Access information:Date:Tuesday, ... 505-4369 (U.S. and Canada) or (719) 325-2315 Conference ... under "Investor Relations"The teleconference replay will be available ... 2014 at (888) 203-1112 (U.S. and ...
(Date:8/20/2014)... Toronto, Canada (PRWEB) August 20, 2014 ... wisdom that E&L studies should be performed late in ... system is known. But current regulatory trends suggest that, ... are on the rise. In recent years, multiple drug ... E&L packages or address specific questions during phase I/II. ...
(Date:8/19/2014)... August 20, 2014 One of ... medicine is an inadequate vascular supply. Nutrient and ... decellularized tissues is critical for successful regeneration and ... to mitigate deficiencies in vascularization and promote angiogenesis ... bioactivity, optimizing scaffold design and architecture, and enhancing ...
Breaking Biology Technology:RENU 28 Skin Care Now Available in Australia and New Zealand 2Neurotrope To Host Conference Call 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2
... Helix BioPharma Corp. (TSX, FSE: "HBP") announced ... in Germany to initiate its planned Phase II ... with low-grade cervical lesions.The clinical study was designed, ... on the absorption and elimination profile of Topical ...
... Percent of Outstanding Indevus Shares Have Been Accepted ... Pharmaceuticals (Nasdaq: ENDP ) announced today ... time, on March 13, 2009, approximately 71,008,964 shares ... were validly tendered and accepted for purchase in ...
... PortfolioNEW YORK, March 16 Samtheo Biopharma LLC ... subsidiary, Lyndor Biosciences LLC, with Moffitt Cancer Center, ... that selectively inhibits the activation of all three ... pathway has been found to play an important ...
Cached Biology Technology:Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 2Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 3Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 4Helix BioPharma Receives Approval to Initiate Phase II Pharmacokinetic Clinical Study of Topical Interferon Alpha-2b in Patients with Low-Grade Cervical Lesions 5Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 2Endo Pharmaceuticals Extends Subsequent Offering Period for Indevus Shares Until 5:00 pm EDT on Wednesday, March 18, 2009 3Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 2Samtheo Announces License Agreement with Moffitt Cancer Center for Exclusive Rights to Novel Akt Inhibitor 3
(Date:8/21/2014)... 2014 Nxt-ID, Inc. (OTCQB: NXTD), a biometric ... announced today that its shares of common stock and ... in its proposed underwritten public offering of common stock ... Nasdaq Capital Market, subject to closing of its proposed ... and will trade under the symbol "NXTD" and "NXTDW," ...
(Date:8/21/2014)... a previously unknown process for harvesting energy and producing ... Penn State University scientist has discovered. The discovery lays ... growth, harvesting energy from the Sun, and understanding dense ... other lakes worldwide. A paper describing the discovery will ... of the journal Science on 21 August ...
(Date:8/21/2014)... easy to ignore, but they are the ultimate source ... Humans are increasingly dependent on algae, too, to suck ... it to the bottom of the ocean. Now, by ... researchers have evidence showing that viruses infecting those algae ... even when all else stays essentially the same, and ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Hot-spring bacteria reveal ability to use far-red light for photosynthesis 2Hot-spring bacteria reveal ability to use far-red light for photosynthesis 3Viruses take down massive algal blooms, with big implications for climate 2
... (hNoV), also known as the winter vomiting bug, is one ... virus is highly contagious, causing vomiting and diarrhea, and the ... cure; sufferers have to let the virus run its course ... is frequently associated with outbreaks of hNoV but it remains ...
... The human skin is home to countless microorganisms that we ... Our invisible passengers known as the skin microbiome - ... immune system, protecting us from pathogens, and mediating skin disorders. ... is transmitted between players in a contact sport, using roller ...
... in French . Researchers at the University ... discovered a new mechanism that allows some cells in our body ... by Roman soldiers depicted in the Asterix series. Collective cell migration ... but it is also used by cancerous cells to disseminate efficiently ...
Cached Biology News:What impact does a day of roller derby have on our skin microbiome? 2Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow 2
Mouse monoclonal [1C6/2] to Rad17 ( Abpromise for all tested applications). entrezGeneID: 5884 SwissProtID: Q9UPF5...
... Spin Columns contain a proprietary high-performance desalting ... desalting and protein-recovery characteristics compared to other ... as 25 g/ml of protein can be ... 95% retention of salts and other small ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
... Immunogen: ... acids 22-37 SGHKSEEKREKMKRTL Antigen ... G-protein signalling; Antigen Subfamily: ... G-protein signalling Recommended Storage: ...
Biology Products: